Microneedle-based nanodrugs for tumor immunotherapy
Journal of Controlled Release · 2025-04 · 380 · 539-562
DOI: 10.1016/j.jconrel.2025.02.003 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Controlled Release, 2025-04. Verfasst von Tianye Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang 110001, China; Key Laboratory of Precis…. Hauptthemen laut MEDLINE: Immunotherapy, Neoplasms, Needles, Drug Delivery Systems. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 169 Literaturangaben. Gefördert von: Liaoning Revitalization Talents Program, National Key Research and Development Program of China Stem Cell and Translational Research, National Key Research and Development Program of China.
Abstract (Originalsprache)
Microneedles have emerged as a promising and effective method for delivering therapeutic drugs and immunobiologics to treat various diseases. It is widely recognized that immune therapy has limited efficacy in solid tumors due to physical barriers and the immunosuppressive tumor microenvironment. Microneedle-based nanodrugs (NDMNs) offer a novel approach to overcome these limitations. These tiny needles are designed to load a variety of inorganic and organic nanoparticles, antigen vaccines, gene drugs, oncolytic viruses, and more. Utilizing microneedle arrays, NDMNs can effectively penetrate the skin barrier, delivering drugs precisely to the tumor site or immunoactive regions within the skin. Additionally, by designing and optimizing the microneedle structure, shape, and functionality, NDMNs enable precise drug release and efficient penetration, thereby enhancing the efficacy of tumor immunotherapy. In this review, we comprehensively discuss the pivotal role of NDMNs in cancer immunotherapy, summarizing innovative microneedle design strategies, mechanisms of immune activation, and delivery strategies of various nanodrugs. Furthermore, we explore the current clinical realities, limitations, and future prospects of NDMNs in tumor immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang 110001, China; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, China Medical…
- Department of Medical Oncology, the First Hospital of China Medical University, Shenyang 110001, China; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical Univers…
- Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China; Joint International Research Laboratory of Intelligent Drug Delivery Systems Ministry of Education, Shenyang 110016, China. Electro…
Förderung
- Liaoning Revitalization Talents Program
- National Key Research and Development Program of China Stem Cell and Translational Research
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Wang, T., Liu, H., Li, M., Ji, Z., Zhang, X., Wang, N., Chen, Y., Sun, J., & Liu, F. (2025). Microneedle-based nanodrugs for tumor immunotherapy. Journal of Controlled Release, 380, 539-562. https://doi.org/10.1016/j.jconrel.2025.02.003
Vancouver
Wang T, Liu H, Li M, Ji Z, Zhang X, Wang N, et al. Microneedle-based nanodrugs for tumor immunotherapy. Journal of Controlled Release. 2025;380:539-562. doi:10.1016/j.jconrel.2025.02.003
BibTeX
@article{Wang2025,
author = {Wang, Tianye and Liu, Hongyu and Li, Meng and Ji, Zao and Zhang, Xinyuan and Wang, Nan and Chen, Ying and Sun, Jin and Liu, Funan},
title = {Microneedle-based nanodrugs for tumor immunotherapy},
journal = {Journal of Controlled Release},
year = {2025},
volume = {380},
pages = {539--562},
doi = {10.1016/j.jconrel.2025.02.003}
}
EUVIMED